Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease
Objectives Autonomic symptoms are present in early stages of Parkinson's disease (PD), but evidence on how they are influenced by dopaminergic treatment remains unclear. The aim of this study was to investigate the impact of dopaminergic treatment on autonomic symptoms in early PD in a populati...
Gespeichert in:
| Veröffentlicht in: | Acta neurologica Scandinavica 2013-04, Vol.127 (4), p.290-294 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 294 |
|---|---|
| container_issue | 4 |
| container_start_page | 290 |
| container_title | Acta neurologica Scandinavica |
| container_volume | 127 |
| creator | Müller, B. Assmus, J. Larsen, J. P. Haugarvoll, K. Skeie, G. O. Tysnes, O.-B. |
| description | Objectives
Autonomic symptoms are present in early stages of Parkinson's disease (PD), but evidence on how they are influenced by dopaminergic treatment remains unclear. The aim of this study was to investigate the impact of dopaminergic treatment on autonomic symptoms in early PD in a population‐based cohort.
Methods
A total of 171 drug‐naive patients with PD were investigated at diagnosis and 12 months later. Orthostatic blood pressure was measured, and autonomic symptoms were assessed by a preliminary version of the Movement Disorders Society‐sponsored new version of the Unified Parkinson's Disease Rating Scale (range 0–4).
Results
In the 82% using dopaminergic treatment after 1 year, constipation and orthostatic blood pressure drop increased. There was a tendency towards increased orthostatic dizziness and urinary dysfunction. Dysphagia scores were reduced, and this was associated with higher levodopa‐equivalent daily dose.
Conclusions
Dopaminergic treatment during the first year after initiation seems to have only a minor impact on autonomic symptoms in early PD. It may increase constipation and orthostatic dizziness, while dysphagia can improve. Autonomic symptoms remained mild after 1 year of dopaminergic treatment. |
| doi_str_mv | 10.1111/ane.12010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1317848959</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2920282391</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3910-625626da204b38bfd2333c7fc700d455b914befc8e28e84f0bb15cfcce537ade3</originalsourceid><addsrcrecordid>eNp1kE1LHDEYgIMoumoP_QNlwEPtYTSfM5njdtFVWK2FlkIvIZO8U2J3kjWZUfffm7rqQWguIeR5H14ehD4SfELyOdUeTgjFBG-hCakwLjHHfBtNMMakrBjhe2g_pdv8ojXnu2iP0qaRRMgJWkzHIfjQO1Okdb8aQp8K7W1hw0r3zkP8k3-GCHrowQ-F84WFwof7UNzo-Nf5FPznVFiXQCc4RDudXib48HIfoJ_nZz9mF-Xi2_xyNl2UhjUElxUVFa2sppi3TLadpYwxU3emxthyIdqG8BY6I4FKkLzDbUuE6YwBwWptgR2g4413FcPdCGlQvUsGlsscIoxJEUZqyWUjmowevUNvwxh93u6Z4o2sRJWpLxvKxJBShE6tout1XCuC1b_EKpvVc-LMfnoxjm0P9o18bZqB0w3w4Jaw_r9JTa_PXpXlZsKlAR7fJnJgVdWsFurX9Vxd_T5vvl99nSvOngAqcZPq</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1317498656</pqid></control><display><type>article</type><title>Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Müller, B. ; Assmus, J. ; Larsen, J. P. ; Haugarvoll, K. ; Skeie, G. O. ; Tysnes, O.-B.</creator><creatorcontrib>Müller, B. ; Assmus, J. ; Larsen, J. P. ; Haugarvoll, K. ; Skeie, G. O. ; Tysnes, O.-B. ; ParkWest study group ; the ParkWest study group</creatorcontrib><description>Objectives
Autonomic symptoms are present in early stages of Parkinson's disease (PD), but evidence on how they are influenced by dopaminergic treatment remains unclear. The aim of this study was to investigate the impact of dopaminergic treatment on autonomic symptoms in early PD in a population‐based cohort.
Methods
A total of 171 drug‐naive patients with PD were investigated at diagnosis and 12 months later. Orthostatic blood pressure was measured, and autonomic symptoms were assessed by a preliminary version of the Movement Disorders Society‐sponsored new version of the Unified Parkinson's Disease Rating Scale (range 0–4).
Results
In the 82% using dopaminergic treatment after 1 year, constipation and orthostatic blood pressure drop increased. There was a tendency towards increased orthostatic dizziness and urinary dysfunction. Dysphagia scores were reduced, and this was associated with higher levodopa‐equivalent daily dose.
Conclusions
Dopaminergic treatment during the first year after initiation seems to have only a minor impact on autonomic symptoms in early PD. It may increase constipation and orthostatic dizziness, while dysphagia can improve. Autonomic symptoms remained mild after 1 year of dopaminergic treatment.</description><identifier>ISSN: 0001-6314</identifier><identifier>EISSN: 1600-0404</identifier><identifier>DOI: 10.1111/ane.12010</identifier><identifier>PMID: 22998158</identifier><identifier>CODEN: ANRSAS</identifier><language>eng</language><publisher>Denmark: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antiparkinson Agents - therapeutic use ; autonomic ; Autonomic Nervous System Diseases - drug therapy ; Autonomic Nervous System Diseases - etiology ; Cohort Studies ; Dopamine Agents - therapeutic use ; dopamine agonist ; epidemiology ; Female ; Humans ; levodopa ; Male ; Middle Aged ; Parkinson ; Parkinson Disease - complications ; Parkinson Disease - drug therapy ; Severity of Illness Index ; Treatment Outcome</subject><ispartof>Acta neurologica Scandinavica, 2013-04, Vol.127 (4), p.290-294</ispartof><rights>2012 John Wiley & Sons A/S</rights><rights>2012 John Wiley & Sons A/S.</rights><rights>Copyright © 2013 John Wiley & Sons A/S</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3910-625626da204b38bfd2333c7fc700d455b914befc8e28e84f0bb15cfcce537ade3</citedby><cites>FETCH-LOGICAL-c3910-625626da204b38bfd2333c7fc700d455b914befc8e28e84f0bb15cfcce537ade3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fane.12010$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fane.12010$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22998158$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Müller, B.</creatorcontrib><creatorcontrib>Assmus, J.</creatorcontrib><creatorcontrib>Larsen, J. P.</creatorcontrib><creatorcontrib>Haugarvoll, K.</creatorcontrib><creatorcontrib>Skeie, G. O.</creatorcontrib><creatorcontrib>Tysnes, O.-B.</creatorcontrib><creatorcontrib>ParkWest study group</creatorcontrib><creatorcontrib>the ParkWest study group</creatorcontrib><title>Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease</title><title>Acta neurologica Scandinavica</title><addtitle>Acta Neurol Scand</addtitle><description>Objectives
Autonomic symptoms are present in early stages of Parkinson's disease (PD), but evidence on how they are influenced by dopaminergic treatment remains unclear. The aim of this study was to investigate the impact of dopaminergic treatment on autonomic symptoms in early PD in a population‐based cohort.
Methods
A total of 171 drug‐naive patients with PD were investigated at diagnosis and 12 months later. Orthostatic blood pressure was measured, and autonomic symptoms were assessed by a preliminary version of the Movement Disorders Society‐sponsored new version of the Unified Parkinson's Disease Rating Scale (range 0–4).
Results
In the 82% using dopaminergic treatment after 1 year, constipation and orthostatic blood pressure drop increased. There was a tendency towards increased orthostatic dizziness and urinary dysfunction. Dysphagia scores were reduced, and this was associated with higher levodopa‐equivalent daily dose.
Conclusions
Dopaminergic treatment during the first year after initiation seems to have only a minor impact on autonomic symptoms in early PD. It may increase constipation and orthostatic dizziness, while dysphagia can improve. Autonomic symptoms remained mild after 1 year of dopaminergic treatment.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antiparkinson Agents - therapeutic use</subject><subject>autonomic</subject><subject>Autonomic Nervous System Diseases - drug therapy</subject><subject>Autonomic Nervous System Diseases - etiology</subject><subject>Cohort Studies</subject><subject>Dopamine Agents - therapeutic use</subject><subject>dopamine agonist</subject><subject>epidemiology</subject><subject>Female</subject><subject>Humans</subject><subject>levodopa</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Parkinson</subject><subject>Parkinson Disease - complications</subject><subject>Parkinson Disease - drug therapy</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><issn>0001-6314</issn><issn>1600-0404</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1LHDEYgIMoumoP_QNlwEPtYTSfM5njdtFVWK2FlkIvIZO8U2J3kjWZUfffm7rqQWguIeR5H14ehD4SfELyOdUeTgjFBG-hCakwLjHHfBtNMMakrBjhe2g_pdv8ojXnu2iP0qaRRMgJWkzHIfjQO1Okdb8aQp8K7W1hw0r3zkP8k3-GCHrowQ-F84WFwof7UNzo-Nf5FPznVFiXQCc4RDudXib48HIfoJ_nZz9mF-Xi2_xyNl2UhjUElxUVFa2sppi3TLadpYwxU3emxthyIdqG8BY6I4FKkLzDbUuE6YwBwWptgR2g4413FcPdCGlQvUsGlsscIoxJEUZqyWUjmowevUNvwxh93u6Z4o2sRJWpLxvKxJBShE6tout1XCuC1b_EKpvVc-LMfnoxjm0P9o18bZqB0w3w4Jaw_r9JTa_PXpXlZsKlAR7fJnJgVdWsFurX9Vxd_T5vvl99nSvOngAqcZPq</recordid><startdate>201304</startdate><enddate>201304</enddate><creator>Müller, B.</creator><creator>Assmus, J.</creator><creator>Larsen, J. P.</creator><creator>Haugarvoll, K.</creator><creator>Skeie, G. O.</creator><creator>Tysnes, O.-B.</creator><general>Blackwell Publishing Ltd</general><general>Hindawi Limited</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201304</creationdate><title>Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease</title><author>Müller, B. ; Assmus, J. ; Larsen, J. P. ; Haugarvoll, K. ; Skeie, G. O. ; Tysnes, O.-B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3910-625626da204b38bfd2333c7fc700d455b914befc8e28e84f0bb15cfcce537ade3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antiparkinson Agents - therapeutic use</topic><topic>autonomic</topic><topic>Autonomic Nervous System Diseases - drug therapy</topic><topic>Autonomic Nervous System Diseases - etiology</topic><topic>Cohort Studies</topic><topic>Dopamine Agents - therapeutic use</topic><topic>dopamine agonist</topic><topic>epidemiology</topic><topic>Female</topic><topic>Humans</topic><topic>levodopa</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Parkinson</topic><topic>Parkinson Disease - complications</topic><topic>Parkinson Disease - drug therapy</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Müller, B.</creatorcontrib><creatorcontrib>Assmus, J.</creatorcontrib><creatorcontrib>Larsen, J. P.</creatorcontrib><creatorcontrib>Haugarvoll, K.</creatorcontrib><creatorcontrib>Skeie, G. O.</creatorcontrib><creatorcontrib>Tysnes, O.-B.</creatorcontrib><creatorcontrib>ParkWest study group</creatorcontrib><creatorcontrib>the ParkWest study group</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Acta neurologica Scandinavica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Müller, B.</au><au>Assmus, J.</au><au>Larsen, J. P.</au><au>Haugarvoll, K.</au><au>Skeie, G. O.</au><au>Tysnes, O.-B.</au><aucorp>ParkWest study group</aucorp><aucorp>the ParkWest study group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease</atitle><jtitle>Acta neurologica Scandinavica</jtitle><addtitle>Acta Neurol Scand</addtitle><date>2013-04</date><risdate>2013</risdate><volume>127</volume><issue>4</issue><spage>290</spage><epage>294</epage><pages>290-294</pages><issn>0001-6314</issn><eissn>1600-0404</eissn><coden>ANRSAS</coden><abstract>Objectives
Autonomic symptoms are present in early stages of Parkinson's disease (PD), but evidence on how they are influenced by dopaminergic treatment remains unclear. The aim of this study was to investigate the impact of dopaminergic treatment on autonomic symptoms in early PD in a population‐based cohort.
Methods
A total of 171 drug‐naive patients with PD were investigated at diagnosis and 12 months later. Orthostatic blood pressure was measured, and autonomic symptoms were assessed by a preliminary version of the Movement Disorders Society‐sponsored new version of the Unified Parkinson's Disease Rating Scale (range 0–4).
Results
In the 82% using dopaminergic treatment after 1 year, constipation and orthostatic blood pressure drop increased. There was a tendency towards increased orthostatic dizziness and urinary dysfunction. Dysphagia scores were reduced, and this was associated with higher levodopa‐equivalent daily dose.
Conclusions
Dopaminergic treatment during the first year after initiation seems to have only a minor impact on autonomic symptoms in early PD. It may increase constipation and orthostatic dizziness, while dysphagia can improve. Autonomic symptoms remained mild after 1 year of dopaminergic treatment.</abstract><cop>Denmark</cop><pub>Blackwell Publishing Ltd</pub><pmid>22998158</pmid><doi>10.1111/ane.12010</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0001-6314 |
| ispartof | Acta neurologica Scandinavica, 2013-04, Vol.127 (4), p.290-294 |
| issn | 0001-6314 1600-0404 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1317848959 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Aged, 80 and over Antiparkinson Agents - therapeutic use autonomic Autonomic Nervous System Diseases - drug therapy Autonomic Nervous System Diseases - etiology Cohort Studies Dopamine Agents - therapeutic use dopamine agonist epidemiology Female Humans levodopa Male Middle Aged Parkinson Parkinson Disease - complications Parkinson Disease - drug therapy Severity of Illness Index Treatment Outcome |
| title | Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T06%3A21%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Autonomic%20symptoms%20and%20dopaminergic%20treatment%20in%20de%20novo%20Parkinson's%20disease&rft.jtitle=Acta%20neurologica%20Scandinavica&rft.au=M%C3%BCller,%20B.&rft.aucorp=ParkWest%20study%20group&rft.date=2013-04&rft.volume=127&rft.issue=4&rft.spage=290&rft.epage=294&rft.pages=290-294&rft.issn=0001-6314&rft.eissn=1600-0404&rft.coden=ANRSAS&rft_id=info:doi/10.1111/ane.12010&rft_dat=%3Cproquest_cross%3E2920282391%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1317498656&rft_id=info:pmid/22998158&rfr_iscdi=true |